Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

The Third Xiangya Hospital of Central South University is the lead sponsor of 27 current clinical trials in our China register. 20 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Benmelstobart. The most-studied condition is Intestinal Ultrasound.

ClinicalTrials.gov trials by status

Recruiting2074%
Not yet open415%
By invitation311%

Trials by phase

Not applicable1348%
Observational1037%
Phase 227%
Phase 314%
Phase EARLY_PHASE114%

Clinical trials sponsored by The Third Xiangya Hospital of Central South University

27 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study NCT07093294 · ClinicalTrials.gov ↗ · Crohn Disease (CD), Vedolizumab, Intestinal Ultrasound	Observational	Recruiting	2025-06	China
A Real-World Study Comparing the Efficacy of Different Treatment Regimens for Early Missed Abortion NCT07422506 · ClinicalTrials.gov ↗ · Missed Abortion, Early Pregnancy Failure	Not applicable	Recruiting	2024-01	China
To Evaluate the Safety and Effectiveness of Intrauterine Adhesion Preventer in the Prevention and Treatment of Intrauterine Adhesions, a Prospective, Multicenter, Randomized Controlled Clinical Trial NCT07611474 · ClinicalTrials.gov ↗ · Intrauterine Adhesion, Intrauterine Adhesions	Not applicable	Recruiting	2021-01	China
Correlation of Blood Serum Renalase and Microcirculation Obstruction in Patients with Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention NCT06669520 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction	Observational	Recruiting	2024-08	China
A Multicenter, Prospective, Randomized, Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resection on the Natural Pregnancy Outcomes in Patients With Non-recurrent Spontaneous Abortion NCT07039097 · ClinicalTrials.gov ↗ · Infertility and Miscarriage	Not applicable	Recruiting	2025-06	China
A Prospective Multicenter Observational Real-world Study of Retained Products of Conception NCT07421895 · ClinicalTrials.gov ↗ · Retained Products of Conception, RPOC	Observational	Recruiting	2022-06	China
Clinical Research on a Novel Deep-learning Based System in Pancreatic Endoscopic Ultrasound Scanning NCT05792267 · ClinicalTrials.gov ↗ · Pancreatic Disease	Not applicable	Recruiting	2021-01	China
Validation of an AI-Assisted Mediastinal EUS System for Training Improvement: a Prospective, Multi-Center, Randomized Trial NCT06790108 · ClinicalTrials.gov ↗ · Mediastinal Disease	Not applicable	Recruiting	2025-01	China
A Multicenter, Prospective, Randomized Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resection on IVF-ET Outcomes in Infertile Patients With Non-recurrent Miscarriage NCT07611656 · ClinicalTrials.gov ↗ · Infertility and Miscarriage	Not applicable	Recruiting	2025-06	China
Establishment of a Classification System and Postoperative Risk Warning Model for Patients Undergoing Bariatric Metabolic Surgery for Severe Obesity NCT07093502 · ClinicalTrials.gov ↗ · Obesity, Bariatric Surgery, Bariatric Surgery (Sleeve Gastrectomy )	Observational	Recruiting	2025-04	China
Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease NCT07123207 · ClinicalTrials.gov ↗ · Mild to Severe Crohns Disease	Not applicable	Recruiting	2025-08	China
Clinical Research on a Novel Deep-learning Based System in Mediastinal Endoscopic Ultrasound Scanning NCT05792280 · ClinicalTrials.gov ↗ · Mediastinum Disease	Not applicable	Recruiting	2021-01	China
Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients NCT07042321 · ClinicalTrials.gov ↗ · Acute Myocardial Infarction (AMI)	Observational	Recruiting	2024-06	China
Validation of an AI-Assisted Pancreatic EUS System for Training Improvement: a Prospective, Multi-Center, Randomized Trial NCT06790134 · ClinicalTrials.gov ↗ · Pancreatic Diseases	Not applicable	Recruiting	2025-01	China
IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study NCT07034664 · ClinicalTrials.gov ↗ · Crohn's Disease, Guselkumab, Intestinal Ultrasound	Observational	Recruiting	2025-06	China
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients NCT07138755 · ClinicalTrials.gov ↗ · NSCLC, Sintilimab, Adaptive Radiotherapy	Phase 2	Recruiting	2025-08	China
Investigating the Association Between Diagnostic and Therapeutic Management Models and Prognosis of Intrauterine Adhesions Based on a Large-Scale Prospective Cohort Study NCT07421908 · ClinicalTrials.gov ↗ · Intrauterine Adhesion	Not applicable	Recruiting	2025-03	China
A Large-scale, Prospective Cohort Study Was Conducted to Explore the Association Between Environmental Exposure and Behavioral Factors and Infertility (the Success Rate of Assisted Reproductive Technology) NCT07641387 · ClinicalTrials.gov ↗ · Infertility, Infertility Assisted Reproductive Technology, Infertility (IVF Patients)	Not applicable	Recruiting	2025-04	China
Environmental and Behavioral Factors in Infertility and ART Outcomes NCT07384676 · ClinicalTrials.gov ↗ · Environmental Exposure, Assisted Reproductive Technology, Prospective Study	Observational	Recruiting	2024-12	China
Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and Exploring Its Impact on Tumor Diagnosis and Prognosis. NCT06655233 · ClinicalTrials.gov ↗ · Pancreatic Cancer, EUS-FNB, Intratumoral Microbiota	Observational	Recruiting	2024-10	China
PK/PD Study of Anti-Infective Drugs in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation Treatment NCT06319677 · ClinicalTrials.gov ↗ · Critical Illness, Extracorporeal Membrane Oxygenation Complication	Observational	Not yet open	2024-05	China
Couple-Coordinated Lifestyle Intervention for Women With a History of Gestational Diabetes Mellitus NCT07762625 · ClinicalTrials.gov ↗ · Diabetes Prevention, GDM, Lifestyle Intervention	Not applicable	Not yet open	2026-08	China
Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC NCT07643350 · ClinicalTrials.gov ↗ · NSCLC Drug: Benmelstobart	Phase 2	Not yet open	2026-05	China
A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer NCT07231094 · ClinicalTrials.gov ↗ · Pancreatic Cancer Metastatic	Phase EARLY_PHASE1	Not yet open	2025-11	China
Precision Antithrombotic Therapy NCT07654634 · ClinicalTrials.gov ↗ · Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE), MI(Myocardial Infarction)	Observational	By invitation	2026-05	China
The Effect of Nurse-led Health Coaching on Blood Pressure Control and Disease Self-management Among Patients With Hypertension in Huayuan County, Western Hunan, China: a Randomized Controlled Trial NCT07606768 · ClinicalTrials.gov ↗ · Hypertension (HTN)	Not applicable	By invitation	2025-11	China
Efficacy and Safety of HRS-9190 in General Anesthesia NCT07733245 · ClinicalTrials.gov ↗ · Adult Participants Requiring Tracheal Intubation Under General Anesthesia for Elective Surgery	Phase 3	By invitation	2026-09	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in The Third Xiangya Hospital of Central South University trials

1 compound

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Benmelstobart1

Conditions in The Third Xiangya Hospital of Central South University trials

49 conditions

Intestinal Ultrasound2Predictor2Intrauterine Adhesion2Infertility and Miscarriage2NSCLC2 Critical Illness1Extracorporeal Membrane Oxygenation Complication1Crohn Disease (CD)1Vedolizumab1Missed Abortion1Early Pregnancy Failure1Intrauterine Adhesions1Acute Myocardial Infarction1Diabetes Prevention1GDM1Lifestyle Intervention1Couples1Retained Products of Conception1RPOC1Pancreatic Disease1Mediastinal Disease1Non-valvular Atrial Fibrillation (NVAF)1Venous Thromboembolism (VTE)1MI(Myocardial Infarction)1

By trial register

Register	Trials	Recruiting
Clinical trials in China	27	20

A trial with sites in more than one country appears in each of those registers.

Questions about The Third Xiangya Hospital of Central South University trials

How many clinical trials does The Third Xiangya Hospital of Central South University sponsor?

The Third Xiangya Hospital of Central South University is the lead sponsor of 27 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are The Third Xiangya Hospital of Central South University trials recruiting?

Yes. 20 of its 27 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is The Third Xiangya Hospital of Central South University testing?

Its current trials name 1 drug or biological as interventions. The most frequent are Benmelstobart (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

The Third Xiangya Hospital of Central South University clinical trials